Xeris Pharmaceuticals Glucagon vs. Others: Product Composition & Efficacy
Published: July 18, 2026 13:12
Author: Marco Thompson
Abstract: Xeris’ ready-to-use glucagon (Gvoke) leverages a non-aqueous, low-volume formulation to eliminate reconstitution, offering superior stability vs. traditional lyophilized kits (Eli Lilly’s Baqsimi, Novo Nordisk’s Zegalogue). Clinical data show comparable efficacy in raising blood glucose, with Xeris’ auto-injector reducing user error. The peptide market trends toward room-temperature stable, patient-centric devices. Xeris’ proprietary XeriJect technology avoids excipient-related degradation, a key advantage over aqueous competitors. Regulatory approvals (FDA) and robust cold-chain logistics enhance its positioning. For buyers, prioritize formulation stability, device ergonomics, and manufacturer GMP certifications.